Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer

Authors: Keigo Mitsui, Masaoki Yonezawa, Atsushi Tatsuguchi, Seiichi Shinji, Katya Gudis, Shu Tanaka, Shunji Fujimori, Choitsu Sakamoto

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

The ErbB family consists of four proteins including (EGFR)/ErbB1, ErbB2, ErbB3, and ErbB4, and plays a crucial role in the promotion of multiple tumorigenic processes. In addition to the traditional pathways of EGFR signaling, EGFR translocates to the nucleus and acts as a transcription factor in the proliferation of cancer cells. Heregulin is known as both an ErbB3 and an ErbB4 ligand. This study aimed to investigate the expression of heregulin and its relevant EGFR family members as well as their phosphorylated forms in human colorectal cancer (CRC) tissues and to determine the relationship between their expression and clinicopathological factors including patient prognosis.

Methods

We analyzed the effects of exogenous heregulin on ErbB2, ErbB3 and ErbB4 phosphorylation in Caco-2, DLD-1, and HCT 116 colon cancer cell lines by western blot analysis. We examined 155 surgical resections from colorectomy patients. Cellular localization of ErbB1-4, their phosphorylated forms and heregulin protein was analyzed in CRC surgical resections by immunohistochemical analysis. Immunohistochemical results were compared with clinicopathological factors and patient prognosis.

Results

Phosphorylated ErbB2 (pErbB2) and phosphorylated ErbB3 (pErbB3) were detected in both nuclear and cytosolic fractions of Caco-2 and DLD-1 cells stimulated by exogenous heregulin. Whereas, phosphorylated ErbB4 (pErbB4) was detected only in cytosolic fractions of HCT 116 cells stimulated by exogenous heregulin. Phosphorylated EGFR (pEGFR) immunoreactivity was observed in the cytoplasm and nuclei of cancer cells, whereas the pattern of EGFR staining was membranous and cytoplasmic. Subcellular localization of pErbB2, cytoplasmic, membranous, or nuclear, varied among cases. pErbB3 immunoreactivity was exclusively observed in the nuclei of cancer cells. pErbB4 immunoreactivity was observed in the cell membrane of cancer cells. Statistically, heregulin immunoreactivity correlated with pErbB2 and pErbB4 expression. In multivariate analysis for disease free survival, lymph node status, pErbB3 and pErbB4 expression retained independent prognostic significance. In multivariate analysis for overall survival, lymph node status, pEGFR and pErbB4 retained independent prognostic significance.

Conclusions

ErbB2 and ErbB3 phosphorylated by heregulin localized in the nucleus of CRC cells. Phosphorylated ErbB1-4 and heregulin contribute to poorer patient prognosis in CRC. This heregulin-ErbB family member autocrine loop may be a candidate for targeted treatment of CRC.
Appendix
Available only for authorised users
Literature
1.
Alroy I, Yarden Y: The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 1997, 410 (1): 83-86. 10.1016/S0014-5793(97)00412-2.CrossRefPubMed
2.
Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006, 366 (1): 2-16. 10.1016/j.gene.2005.10.018.CrossRefPubMed
3.
Ocana A, Pandiella A: Targeting HER receptors in cancer. Curr Pharm Des. 2013, 19 (5): 808-817. 10.2174/138161213804547303.CrossRefPubMed
4.
Khelwatty SA, Essapen S, Seddon AM, Modjtahedi H: Prognostic significance and targeting of HER family in colorectal cancer. Front Biosci (Landmark Ed). 2013, 18: 394-421. 10.2741/4110.CrossRef
5.
Karsa LV, Lignini TA, Patnick J, Lambert R, Sauvaget C: The dimensions of the CRC problem. Best Pract Res Clin Gastroenterol. 2010, 24 (4): 381-396. 10.1016/j.bpg.2010.06.004.CrossRefPubMed
6.
Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 2014, 64 (1): 9-29. 10.3322/caac.21208.CrossRefPubMed
7.
Yarom N, Jonker DJ: The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Discov Med. 2011, 11 (57): 95-105.PubMed
8.
Desai MD, Saroya BS, Lockhart AC: Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers. Expert Opin Investig Drugs. 2013, 22 (3): 341-356. 10.1517/13543784.2013.761972.CrossRefPubMed
9.
Lee D, Yu M, Lee E, Kim H, Yang Y, Kim K, Pannicia C, Kurie JM, Threadgill DW: Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. J Clin Invest. 2009, 119 (9): 2702-2713. 10.1172/JCI36435.CrossRefPubMedPubMedCentral
10.
Han W, Lo HW: Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett. 2012, 318 (2): 124-134. 10.1016/j.canlet.2012.01.011.CrossRefPubMedPubMedCentral
11.
Wang YN, Hung MC: Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family. Cell Biosci. 2012, 2 (1): 13-10.1186/2045-3701-2-13.CrossRefPubMedPubMedCentral
12.
Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF, Hung MC: Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res. 2005, 65 (1): 338-348.PubMed
13.
Psyrri A, Egleston B, Weinberger P, Yu Z, Kowalski D, Sasaki C, Haffty B, Rimm D, Burtness B: Correlates and determinants of nuclear epidermal growth factor receptor content in an oropharyngeal cancer tissue microarray. Cancer Epidemiol Biomarkers Prev. 2008, 17 (6): 1486-1492. 10.1158/1055-9965.EPI-07-2684.CrossRefPubMed
14.
Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, Wheeler DL: Nuclear EGFR as a molecular target in cancer. Radiother Oncol. 2013, 108 (3): 370-377. 10.1016/j.radonc.2013.06.010.CrossRefPubMed
15.
Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL: Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene. 2009, 28 (43): 3801-3813. 10.1038/onc.2009.234.CrossRefPubMedPubMedCentral
16.
Xia W, Wei Y, Du Y, Liu J, Chang B, Yu YL, Huo LF, Miller S, Hung MC: Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog. 2009, 48 (7): 610-617. 10.1002/mc.20504.CrossRefPubMedPubMedCentral
17.
Traynor AM, Weigel TL, Oettel KR, Yang DT, Zhang C, Kim K, Salgia R, Iida M, Brand TM, Hoang T, Campbell TC, Hernan HR, Wheeler DL: Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer. 2013, 81 (1): 138-141. 10.1016/j.lungcan.2013.03.020.CrossRefPubMedPubMedCentral
18.
Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol. 1996, 16 (10): 5276-5287.CrossRefPubMedPubMedCentral
19.
Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 1996, 15 (10): 2452-2467.PubMedPubMedCentral
20.
Tzahar E, Levkowitz G, Karunagaran D, Yi L, Peles E, Lavi S, Chang D, Liu N, Yayon A, Wen D, Yarden Y: ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. J Biol Chem. 1994, 269 (40): 25226-25233.PubMed
21.
Breuleux M: Role of heregulin in human cancer. Cell Mol Life Sci. 2007, 64 (18): 2358-2377. 10.1007/s00018-007-7120-0.CrossRefPubMed
22.
Montero JC, Rodriguez-Barrueco R, Ocana A, Diaz-Rodriguez E, Esparis-Ogando A, Pandiella A: Neuregulins and cancer. Clin Cancer Res. 2008, 14 (11): 3237-3241. 10.1158/1078-0432.CCR-07-5133.CrossRefPubMed
23.
Yonezawa M, Wada K, Tatsuguchi A, Akamatsu T, Gudis K, Seo T, Mitsui K, Nagata K, Tanaka S, Fujimori S, Sakamoto C: Heregulin-induced VEGF expression via the ErbB3 signaling pathway in colon cancer. Digestion. 2009, 80 (4): 215-225. 10.1159/000229775.CrossRefPubMed
24.
De Boeck A, Pauwels P, Hensen K, Rummens JL, Westbroek W, Hendrix A, Maynard D, Denys H, Lambein K, Braems G, Gespach C, Bracke M, De Wever O: Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. Gut. 2013, 62 (4): 550-560. 10.1136/gutjnl-2011-301393.CrossRefPubMed
25.
Schreiber E, Matthias P, Muller MM, Schaffner W: Rapid detection of octamer binding proteins with ‘mini-extracts’, prepared from a small number of cells. Nucleic Acids Res. 1989, 17 (15): 6419-10.1093/nar/17.15.6419.CrossRefPubMedPubMedCentral
26.
Li Q, Wang D, Li J, Chen P: Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer. 2011, 11: 277-10.1186/1471-2407-11-277.CrossRefPubMedPubMedCentral
27.
Xu H, Yu Y, Marciniak D, Rishi AK, Sarkar FH, Kucuk O, Majumdar AP: Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Mol Cancer Ther. 2005, 4 (3): 435-442.PubMed
28.
Grivas PD, Antonacopoulou A, Tzelepi V, Sotiropoulou-Bonikou G, Kefalopoulou Z, Papavassiliou AG, Kalofonos H: HER-3 in colorectal tumourigenesis: from mRNA levels through protein status to clinicopathologic relationships. Eur J Cancer. 2007, 43 (17): 2602-2611. 10.1016/j.ejca.2007.08.019.CrossRefPubMed
29.
Castagnino P, Lorenzi MV, Yeh J, Breckenridge D, Sakata H, Munz B, Werner S, Bottaro DP: Neu differentiation factor/heregulin induction by hepatocyte and keratinocyte growth factors. Oncogene. 2000, 19 (5): 640-648. 10.1038/sj.onc.1203357.CrossRefPubMed
30.
Venkateswarlu S, Dawson DM, St Clair P, Gupta A, Willson JK, Brattain MG: Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. Oncogene. 2002, 21 (1): 78-86. 10.1038/sj.onc.1205011.CrossRefPubMed
31.
Huang CW, Tsai HL, Chen YT, Huang CM, Ma CJ, Lu CY, Kuo CH, Wu DC, Chai CY, Wang JY: The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. BMC Cancer. 2013, 13: 599-10.1186/1471-2407-13-599.CrossRefPubMedPubMedCentral
32.
Conradi LC, Styczen H, Sprenger T, Wolff HA, Rodel C, Nietert M, Homayounfar K, Gaedcke J, Kitz J, Talaulicar R, Becker H, Ghadimi M, Middel P, Beissbarth T, Ruschoff J, Liersch T: Frequency of HER-2 positivity in rectal cancer and prognosis. Am J Surg Pathol. 2013, 37 (4): 522-531. 10.1097/PAS.0b013e318272ff4d.CrossRefPubMed
33.
Marx AH, Burandt EC, Choschzick M, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Atanackovic D, Bokemeyer C, Fiedler W, Terracciano L, Sauter G, Izbicki JR: Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol. 2010, 41 (11): 1577-1585. 10.1016/j.humpath.2010.02.018.CrossRefPubMed
34.
Beji A, Horst D, Engel J, Kirchner T, Ullrich A: Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. Clin Cancer Res. 2012, 18 (4): 956-968. 10.1158/1078-0432.CCR-11-1186.CrossRefPubMed
35.
Kapitanovic S, Radosevic S, Slade N, Kapitanovic M, Andelinovic S, Ferencic Z, Tavassoli M, Spaventi S, Pavelic K, Spaventi R: Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol. 2000, 126 (4): 205-211. 10.1007/s004320050034.CrossRefPubMed
36.
Baiocchi G, Lopes A, Coudry RA, Rossi BM, Soares FA, Aguiar S, Guimaraes GC, Ferreira FO, Nakagawa WT: ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. Int J Color Dis. 2009, 24 (9): 1059-1068. 10.1007/s00384-009-0702-6.CrossRef
37.
Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, Patsouris E, Pectasides D, Economopoulos T: Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer. 2006, 6: 46-10.1186/1471-2407-6-46.CrossRefPubMedPubMedCentral
38.
Lee JC, Wang ST, Chow NH, Yang HB: Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer. 2002, 38 (8): 1065-1071. 10.1016/S0959-8049(02)00004-7.CrossRefPubMed
39.
Ljuslinder I, Malmer B, Isaksson-Mettavainio M, Oberg A, Henriksson R, Stenling R, Palmqvist R: ErbB 1–4 expression alterations in primary colorectal cancers and their corresponding metastases. Anticancer Res. 2009, 29 (5): 1489-1494.PubMed
40.
Brand TM, Iida M, Li C, Wheeler DL: The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med. 2011, 12 (66): 419-432.PubMedPubMedCentral
Metadata
Title
Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer
Authors
Keigo Mitsui
Masaoki Yonezawa
Atsushi Tatsuguchi
Seiichi Shinji
Katya Gudis
Shu Tanaka
Shunji Fujimori
Choitsu Sakamoto
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-863

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis

Research article

Tyrosine phosphorylation profiling via in situproximity ligation assay

Research article

Hepatitis B spliced protein (HBSP) promotes the carcinogenic effects of benzo [alpha] pyrene by interacting with microsomal epoxide hydrolase and enhancing its hydrolysis activity

Research article

Helicase-like transcription factor: a new marker of well-differentiated thyroid cancers

Research article

Animal model of naturally occurring bladder cancer: Characterization of four new canine transitional cell carcinoma cell lines

Research article

Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits